Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
10 Moves toward Start Your Own Effective Business - 235 million tons of food go to waste yearly in the US. Experts share tips to help stop it
- 3Chicago reports first rabies-positive dog in 61 years. What we know.
- 4Hubble sees spiral galaxy in Lion's heart | Space photo of the day for Nov. 4
- 5The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
- Instructions to Perform Fundamental Upkeep on Your Slam 1500.
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- EU waters down plans to end new petrol and diesel car sales by 2035
- The Best Web-based Courses for Expertise Improvement
- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- Share your number one city visit transport that leaves a mark on the world wake up!
- Rediscovering Imagination in Adulthood: Individual Creative Excursions
- Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her
